Retina

The company will seek a strategic partner to continue development of APX3330, an oral small-molecule inhibitor of Ref-1 for the treatment of non-proliferative diabetic retinopathy.

The retina is a key proving ground for long-held theories of genetics.

According to a study presented at the American Academy of Ophthalmology’s annual meeting in Chicago, investigational treatment reduced vision loss and protected key structures in the eye essential for vision.

Meghan Berkenstock, MD, an associate professor of ophthalmology at the Wilmer Eye Institute, provides insights on paper from the uveitis free paper section of AAO 2024, about the use of TriNetX database to assess for the incidence and prevalence of both uveitis and its complications.

In data presented at the 128th annual meeting of the American Academy of Ophthalmology in Chicago, the two-year study finds patients with advanced disease can recover some vision.

The investigators conducted a study in which they evaluated the retinal structure in patients with ametropic amblyopia and then correlated it with the final visual acuities achieved after 6 months of follow-up using a multimodal imaging approach.

Tinlarebant is an oral therapy designed to reduce the accumulation of vitamin A based toxins that cause retinal disease.

A recent paper reveals increasing rates of diabetic retinopathy in young patients with diabetes, sparking concerns over inadequate screening and management, especially among Black and Hispanic youths.

According to the company, MCO-010 is an ambient-light activatable Multi-Characteristic Opsin (MCO) optogenetic therapy for vision restoration in advanced retinitis pigmentosa (RP), irrespective of gene mutation.

According to the company, the axitinib injectable suspension achieved all primary and secondary outcomes and maintained stable visual acuity and anatomical control over 9 months.

The effort represents a consortium of researchers from Penn Medicine, Penn Engineering, the University of Michigan Kellogg Eye Center, St. John Eye Hospital in Jerusalem, and Gyeongsang National University College of Medicine in Korea.

Changes associated with Alzheimer's disease extend beyond the brain.

In a study, a team of UCLA investigators detail a deep-learning model pre-trained on 2D scans that accurately predicts disease-risk factors from 3D medical-scan modalities.

The award from the National Institutes of Health will enable a team of researchers to investigate Alzheimer and Parkinson progression through the eye.

Because the inner retinal function is thought to affect the emmetropization process, authors suggested that caffeine may be involved in ocular growth

The company’s flagship product is Reti-CVD, an AI diagnostic solution that autonomously assesses future cardiovascular disease risk using a retina scan.

Lloyd Clark, MD, discusses the evolution and current practices in the treatment of common retinal diseases such as age-related macular degeneration, diabetic macular edema, and retinal vein occlusion.

Adam S. Wenick, MD, PhD, chaired a symposium on geographic atrophy (GA) at EyeCon 2024, focusing on the diagnosis, monitoring, and FDA-approved treatments for GA. The session with Leonard Messner, OD, FAAO, also included case presentations that highlighted key factors for clinicians to consider when selecting appropriate treatment options.

The NIH-supported findings could pave the way for genetic testing, clinical trials, and therapy development for these diseases.

Additionally, FDA grants Fast Track Designation to brepocitinib for non-infectious uveitis.

The data were presented at the Keystone Symposium Targeting Dry Age-related Macular Degeneration: Pathophysiology and Emerging Therapies.

Efferocytosis’ role in retinopathy is largely unknown despite knowledge of the process in other diseases.

Diana Do, MD, spoke with the Ophthalmology Times team about her presentation at the Retina Society meeting focusing on Population Pharmacokinetic Modeling and Simulation of Ocular Clearance for Aflibercept 8 mg and 2 mg.

The announcement marks the second FDA designation for ATSN-201, which previously received Rare Pediatric Disease designation.

Researchers at the Karolinska Institute continue to investigate whether gene therapy can improve vision in people with Bothnia dystrophy, a form of hereditary blindness, prevalent in the region Västerbotten in Sweden.

David A. Eichenbaum, MD, presented key data from two clinical trials focusing on therapies for age-related macular degeneration at the Retina Society 57th Annual Scientific Meeting in Lisbon, Portugal.

Durga Borkar, MD, sat down with Sydney Crago of Modern Retina to discuss one of her presentations on the first time phase 2 clinical trial results for ONL-1204 for rhegmatogenous retinal detachment from the Retina Society meeting being held this year in Lisbon, Portugal.